NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors
SANTA ANA, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (“NKGen” or the…
Durabook Introduces the R12 Rugged Tablet Active Edge AI Platform
IronSight AI and Fast Iron Partner to Bring AI-Powered Inventory Capture to Caterpillar, Komatsu and Volvo Equipment Dealers